Bevacizumab 1.25 mg/0.05 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal Rx -- Pine Pharmaceuticals, 100 Colvin Woods Pkwy Suite 300, Tonawanda, NY 14150.
Publicado el 27 de enero de 2016 · Inicio del retiro: 4 de noviembre de 2015
Resumen
FDA registra el retiro D-0581-2016 de medicamentos de Clase II, publicado el 27 de enero de 2016 e iniciado el 4 de noviembre de 2015. Empresa responsable: Pine Pharmaceuticals, LLC; Estado: Finalizado; Cantidad reportada: N/A; Lote: Lot #: 1956@2, exp. 2/2/2016; 1954@1, exp. 2/2/2016; 1958@3, exp. 2/2/2016; 1943@2, exp. 2/1/2016; 1942@1, exp. 2/1/2016; 1944@3, exp. 2/1/2016; 1938@1, exp. 1/31/2016; 1939@2, exp. 1/31/2016; 1931@1, exp. 1/28/2016; 1932@2, exp. 1/28/2016; 1935@3, exp. 1/28/2016; 1925@1, exp. 1/27/2016; 1927@2, exp. 1/27/2016; 1928@3, exp. 1/27/2016; 1913@3, exp. 1/26/2016; 1917@4, exp. 1/26/2016; 1911@1, exp. 1/26/2016; 1921@6, exp. 1/26/2016; 1906@3, exp. 1/25/2016; 1903@1, exp. 1/25/2016; 1904@2, exp. 1/25/2016; 1899@3, exp. 1/24/2016; 1896@2, exp. 1/24/2016; 1895@1, exp. 1/24/2016; 1886@2, exp. 1/21/2016; 1893@5, exp. 1/21/2016; 1890@4, exp. 1/21/2016; 1885@1, exp. 1/21/2016; 1888@3, exp. 1/21/2016; 1879@5, exp. 1/20/2016; 1872@1, exp. 1/20/2016; 1875@3, exp. 1/20/2016; 1873@2, exp. 1/20/2016; 1867@5, exp. 1/19/2016; 1870@6, exp. 1/19/2016; 1866@4, exp. 1/19/2016; 1854@4, exp. 1/18/2016; 1853@5, exp. 1/18/2016; 1855@6, exp. 1/18/2016; 1839@3, exp. 1/17/2016; 1836@1, exp. 1/17/2016; 1831@2, exp. 1/14/2016; 1813@2, exp. 1/14/2016; 1830@1, exp. 1/14/2016; 1825@1, exp. 1/13/2016; 1818@4, exp. 1/13/2016; 1827@2, exp. 1/13/2016; 1816@3, exp. 1/12/2016; 1812@1, exp. 1/13/2016; 1804@4, exp. 12/31/2015; 1799@6, exp. 1/10/2016; 1797@5, exp. 1/10/2016; 1789@3, exp. 1/7/2016; 1635@5, exp. 12/17/2015; 1490@1, exp. 11/25/2015; 1790@4, exp. 1/7/2016; 1633@4, exp. 12/17/2015; 1492@2, exp. 11/25/2015; 1786@1, exp. 1/7/2016; 1628@2, exp. 12/17/2015; 1497@5, exp. 11/25/2015; 1788@2, exp. 1/7/2016; 1629@3, exp. 12/17/2015; 1486@7, exp. 11/24/2015; 1764@1, exp. 1/6/2016; 1617@1, exp. 12/16/2015; 1476@3, exp. 11/24/2015; 1768@3, exp. 1/6/2016; 1623@4, exp. 12/16/2015; 1474@1, exp. 11/24/2015; 1769@4, exp. 1/6/2016; 1620@3, exp. 12/16/2015; 1466@2, exp. 11/23/2015; 1757@2, exp. 1/5/2016; 1625@5, exp. 12/16/2015; 1473@5, exp. 11/23/2015; 1756@1, exp. 1/5/2016; 1618@2, exp. 12/16/2015; 1465@1, exp. 11/23/2015; 1762@4, exp. 1/5/2016; 1608@2, exp. 12/15/2015; 1460@2, exp. 11/22/2015; 1749@3, exp. 1/4/2016; 1610@3, exp. 12/15/2015; 1458@1, exp. 11/22/2015; 1746@1, exp. 1/4/2016; 1597@2, exp. 12/14/2015; 1450@5, exp. 11/19/2015; 1748@2, exp. 1/4/2016; 1599@4, exp. 12/14/2015; 1447@3, exp. 11/19/2015; 1750@4, exp. 1/4/2016; 1601@5, exp. 12/14/2015; 1448@4, exp. 11/19/2015; 1740@2, exp. 1/3/2016; 1591@1, exp. 12/10/2015; 1436@2, exp. 11/18/2015; 1742@3, exp. 1/3/2016; 1594@3, exp. 12/10/2015; 1441@4, exp. 11/18/2015; 1739@1, exp. 1/3/2016; 1592@2, exp. 12/10/2015; 1443@5, exp. 11/18/2015; 1735@3, exp. 12/31/2015; 1583@3, exp. 12/9/2015; 1439@3, exp. 11/18/2015; 1731@1, exp. 12/31/2015; 1586@4, exp. 12/9/2015; 1435@1, exp. 11/18/2015; 1733@2, exp. 12/31/2015; 1580@1, exp. 12/9/2015; 1423@2, exp. 11/17/2015; 1737@4, exp. 12/31/2015; 1581@2, exp. 12/9/2015; 1433@7, exp. 11/17/2015; 1715@1, exp. 12/30/2015; 1588@5, exp. 12/9/2015; 1422@1, exp. 11/17/2015; 1718@3, exp. 12/30/2015; 1570@1, exp. 12/8/2015; 1417@3, exp. 11/16/2015; 1709@2, exp. 12/29/2015; 1571@2, exp. 12/8/2015; 1416@2, exp. 11/16/2015; 1707@1, exp. 12/29/2015; 1578@5, exp. 12/8/2015; 1420@4, exp. 11/16/2015; 1712@4, exp. 12/29/2015; 1576@4, exp. 12/8/2015; 1413@4, exp. 11/15/2015; 1710@3, exp. 12/29/2015; 1572@3, exp. 12/8/2015; 1412@3, exp. 11/15/2015; 1696@2, exp. 12/28/2015; 1562@1, exp. 12/7/2015; 1396@2, exp. 11/12/2015; 1698@3, exp. 12/28/2015; 1563@2, exp. 12/7/2015; 1402@5, exp. 11/12/2015; 1695@1, exp. 12/28/2015; 1564@3, exp. 12/7/2015; 1398@4, exp. 11/12/2015; 1699@4, exp. 12/28/2015; 1558@1, exp. 12/3/2015; 1392@7, exp. 11/11/2015; 1689@1, exp. 12/27/2015; 1554@4, exp. 12/2/2015; 1388@5, exp. 11/11/2015; 1692@3, exp. 12/27/2015; 1560@2, exp. 12/3/2015; 1385@4, exp. 11/11/2015; 1690@2, exp. 12/27/2015; 1556@5, exp. 12/2/2015; 1372@3, exp. 11/10/2015; 1683@1, exp. 12/24/2015; 1548@1, exp. 12/2/2015; 1371@2, exp. 11/10/2015; 1686@3, exp. 12/24/2015; 1550@3, exp. 12/2/2015; 1369@1, exp. 11/10/2015; 1684@2, exp. 12/24/2015; 1549@2, exp. 12/2/2015; 1360@2, exp. 11/9/2015; 1674@3, exp. 12/23/2015; 1536. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Pine Pharmaceuticals, LLC
- Distribuidor
- Nationwide and Puerto Rico
- Lote
- Lot #: 1956@2, exp. 2/2/2016; 1954@1, exp. 2/2/2016; 1958@3, exp. 2/2/2016; 1943@2, exp. 2/1/2016; 1942@1, exp. 2/1/2016; 1944@3, exp. 2/1/2016; 1938@1, exp. 1/31/2016; 1939@2, exp. 1/31/2016; 1931@1, exp. 1/28/2016; 1932@2, exp. 1/28/2016; 1935@3, exp. 1/28/2016; 1925@1, exp. 1/27/2016; 1927@2, exp. 1/27/2016; 1928@3, exp. 1/27/2016; 1913@3, exp. 1/26/2016; 1917@4, exp. 1/26/2016; 1911@1, exp. 1/26/2016; 1921@6, exp. 1/26/2016; 1906@3, exp. 1/25/2016; 1903@1, exp. 1/25/2016; 1904@2, exp. 1/25/2016; 1899@3, exp. 1/24/2016; 1896@2, exp. 1/24/2016; 1895@1, exp. 1/24/2016; 1886@2, exp. 1/21/2016; 1893@5, exp. 1/21/2016; 1890@4, exp. 1/21/2016; 1885@1, exp. 1/21/2016; 1888@3, exp. 1/21/2016; 1879@5, exp. 1/20/2016; 1872@1, exp. 1/20/2016; 1875@3, exp. 1/20/2016; 1873@2, exp. 1/20/2016; 1867@5, exp. 1/19/2016; 1870@6, exp. 1/19/2016; 1866@4, exp. 1/19/2016; 1854@4, exp. 1/18/2016; 1853@5, exp. 1/18/2016; 1855@6, exp. 1/18/2016; 1839@3, exp. 1/17/2016; 1836@1, exp. 1/17/2016; 1831@2, exp. 1/14/2016; 1813@2, exp. 1/14/2016; 1830@1, exp. 1/14/2016; 1825@1, exp. 1/13/2016; 1818@4, exp. 1/13/2016; 1827@2, exp. 1/13/2016; 1816@3, exp. 1/12/2016; 1812@1, exp. 1/13/2016; 1804@4, exp. 12/31/2015; 1799@6, exp. 1/10/2016; 1797@5, exp. 1/10/2016; 1789@3, exp. 1/7/2016; 1635@5, exp. 12/17/2015; 1490@1, exp. 11/25/2015; 1790@4, exp. 1/7/2016; 1633@4, exp. 12/17/2015; 1492@2, exp. 11/25/2015; 1786@1, exp. 1/7/2016; 1628@2, exp. 12/17/2015; 1497@5, exp. 11/25/2015; 1788@2, exp. 1/7/2016; 1629@3, exp. 12/17/2015; 1486@7, exp. 11/24/2015; 1764@1, exp. 1/6/2016; 1617@1, exp. 12/16/2015; 1476@3, exp. 11/24/2015; 1768@3, exp. 1/6/2016; 1623@4, exp. 12/16/2015; 1474@1, exp. 11/24/2015; 1769@4, exp. 1/6/2016; 1620@3, exp. 12/16/2015; 1466@2, exp. 11/23/2015; 1757@2, exp. 1/5/2016; 1625@5, exp. 12/16/2015; 1473@5, exp. 11/23/2015; 1756@1, exp. 1/5/2016; 1618@2, exp. 12/16/2015; 1465@1, exp. 11/23/2015; 1762@4, exp. 1/5/2016; 1608@2, exp. 12/15/2015; 1460@2, exp. 11/22/2015; 1749@3, exp. 1/4/2016; 1610@3, exp. 12/15/2015; 1458@1, exp. 11/22/2015; 1746@1, exp. 1/4/2016; 1597@2, exp. 12/14/2015; 1450@5, exp. 11/19/2015; 1748@2, exp. 1/4/2016; 1599@4, exp. 12/14/2015; 1447@3, exp. 11/19/2015; 1750@4, exp. 1/4/2016; 1601@5, exp. 12/14/2015; 1448@4, exp. 11/19/2015; 1740@2, exp. 1/3/2016; 1591@1, exp. 12/10/2015; 1436@2, exp. 11/18/2015; 1742@3, exp. 1/3/2016; 1594@3, exp. 12/10/2015; 1441@4, exp. 11/18/2015; 1739@1, exp. 1/3/2016; 1592@2, exp. 12/10/2015; 1443@5, exp. 11/18/2015; 1735@3, exp. 12/31/2015; 1583@3, exp. 12/9/2015; 1439@3, exp. 11/18/2015; 1731@1, exp. 12/31/2015; 1586@4, exp. 12/9/2015; 1435@1, exp. 11/18/2015; 1733@2, exp. 12/31/2015; 1580@1, exp. 12/9/2015; 1423@2, exp. 11/17/2015; 1737@4, exp. 12/31/2015; 1581@2, exp. 12/9/2015; 1433@7, exp. 11/17/2015; 1715@1, exp. 12/30/2015; 1588@5, exp. 12/9/2015; 1422@1, exp. 11/17/2015; 1718@3, exp. 12/30/2015; 1570@1, exp. 12/8/2015; 1417@3, exp. 11/16/2015; 1709@2, exp. 12/29/2015; 1571@2, exp. 12/8/2015; 1416@2, exp. 11/16/2015; 1707@1, exp. 12/29/2015; 1578@5, exp. 12/8/2015; 1420@4, exp. 11/16/2015; 1712@4, exp. 12/29/2015; 1576@4, exp. 12/8/2015; 1413@4, exp. 11/15/2015; 1710@3, exp. 12/29/2015; 1572@3, exp. 12/8/2015; 1412@3, exp. 11/15/2015; 1696@2, exp. 12/28/2015; 1562@1, exp. 12/7/2015; 1396@2, exp. 11/12/2015; 1698@3, exp. 12/28/2015; 1563@2, exp. 12/7/2015; 1402@5, exp. 11/12/2015; 1695@1, exp. 12/28/2015; 1564@3, exp. 12/7/2015; 1398@4, exp. 11/12/2015; 1699@4, exp. 12/28/2015; 1558@1, exp. 12/3/2015; 1392@7, exp. 11/11/2015; 1689@1, exp. 12/27/2015; 1554@4, exp. 12/2/2015; 1388@5, exp. 11/11/2015; 1692@3, exp. 12/27/2015; 1560@2, exp. 12/3/2015; 1385@4, exp. 11/11/2015; 1690@2, exp. 12/27/2015; 1556@5, exp. 12/2/2015; 1372@3, exp. 11/10/2015; 1683@1, exp. 12/24/2015; 1548@1, exp. 12/2/2015; 1371@2, exp. 11/10/2015; 1686@3, exp. 12/24/2015; 1550@3, exp. 12/2/2015; 1369@1, exp. 11/10/2015; 1684@2, exp. 12/24/2015; 1549@2, exp. 12/2/2015; 1360@2, exp. 11/9/2015; 1674@3, exp. 12/23/2015; 1536
- Clasificación de riesgo
- Class II
- Área (FDA)
- drug
- País
- United States
Retiros relacionados
- FDACefuroxime 4mg /0.4 mL (10 mg/mL), 1mL syringe, Rx only, Compounded by: Pine Pharmaceuticals 355 Riverwalk25 de octubre de 2023
- FDAMoxifloxacin in Balanced Salt Solution 400 mcg/0.4 mL (100 mcg/0.1 mL) 1 mL syringes, Rx only, Compounded by:25 de octubre de 2023
- FDACalcium chloride Solution for Intravenous Injection, 20 mg/mL, 500 mL bags, Rx only, Compounded by Pine25 de octubre de 2023
- FDALidocaine-phenylephrine 1%-1.5% 1mL Single Dose Vial, Rx only, Compounded by Pine Pharmaceuticals 35525 de octubre de 2023
- FDAEnergique, Homeopathic Remedy, Headache Pain & Sinus Pressure Relief, Topical Spray, 1 fl oz (30 ml) bottles,27 de enero de 2016
- FDABevacizumab 1.25 mg/0.05 mL filled to 0.06 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal, Rx -- Pine27 de enero de 2016
Preguntas sobre este retiro
¿Bevacizumab 1.25 mg/0.05 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal Rx -- Pine Pharmaceuticals, 100 Colvin Woods Pkwy Suite 300, Tonawanda, NY 14150. fue retirado del mercado?
Sí. FDA publicó el retiro D-0581-2016 el 27 de enero de 2016. Peligro reportado: Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter